Louis, MO Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX The Compass Therapeutics, Brighton, MA Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX Texas Oncology PA, Sherman, TX Texas Oncology - Baylor Charles A. Washington University School of Medicine in St. Key secondary objectives include overall survival, progression-free survival, and duration of response. paclitaxel alone, as measured by Overall Response Rate (ORR) assessed by an Independent Central Radiology (ICR) review. The primary objective of the study is to assess the efficacy of CTX-009 in combination with paclitaxel vs. The patients randomized to paclitaxel arm can crossover after disease progression if selection criteria continue to be met. For more data, refer to the SD topics in the VisiLogic Help system. Patients will be treated in 28-day cycles, with CTX-009 administered at 10 mg/kg IV on Day 1 and 15, and paclitaxel administered at 80 mg/m2 on days 1, 8, and 15. Vision OPLC V570-57-T20B & V570-57-T20B-J User Guide 2 Unitronics Removable Memory Storage SD card: store datalogs, Alarms, Trends, Data Tables export to Excel backup Ladder, HMI & OS and use this data to ‘clone’ PLCs. extrahepatic cholangiocarcinoma, gallbladder, or ampullary), and Eastern Cooperative Oncology Group (ECOG) Performance status (0 vs. metastatic), anatomic subsite of primary tumor (intrahepatic cholangiocarcinoma vs. The stratification factors to be used at randomization include stage (locally advanced vs. 150 patients will be randomized in a 2:1 ratio to receive either CTX-009 plus paclitaxel or paclitaxel alone. To be eligible, patients must have radiologically documented progression after a prior gemcitabine and platinum containing chemotherapy regimen as first line therapy for locally advanced unresectable or metastatic disease. Methods: COMPANION-002 (CTX-009 -002) is an open-label, randomized, controlled study in patients in second line advanced or metastatic BTC. The antibody simultaneously inhibits the DLL4-Notch 1 and VEGF A-VEGF receptor signaling pathways.

Geared Movement: 302 and 304 stainless steel Lens: Optically clear. (114 mm) white on black, dual scaled psi /kPa Gage Accuracy: 2-1-2 ☒ for the first and last quarters of the scale, the middle half is ☑. CTX-009 is a recombinant bispecific antibody that binds both delta-like ligand-4 (DLL4) and vascular endothelial growth factor A (VEGF-A). Contact Ratings: OPLC & OPLFC: 1 SPDT Center off 2A, 30VDC / 0.1 A, 125 VAC. The DLL/Notch signaling pathway has been described to be a major driver of cholangiocarcinogenesis and VEGF-A overexpression has been reported in BTC tumors, correlating with stage, metastasis, and prognosis of the disease. Presently, there is no consensus second-line therapy for patients with BTC.

Systemic chemotherapy usually begins with gemcitabine, platinum agents, and a checkpoint inhibitor followed by 5-FU and oxaliplatin, irinotecan or a taxane. Background: Biliary tract cancer (BTC) is characterized by generally poor prognoses with limited treatment options.

Oplc faceters companion v2.002